Skip navigation
Universidade de Brasília
Use este identificador para citar ou linkar para este item: http://repositorio.unb.br/handle/10482/46737
Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
ARTIGO_EffectivenessSafetyMultidrug.pdf778,61 kBAdobe PDFVisualizar/Abrir
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorMontezuma, Thais-
dc.contributor.authorVernal, Sebastian-
dc.contributor.authorAndrade, Elaine Nascimento-
dc.contributor.authorBrandão, Jurema Guerrieri-
dc.contributor.authorOliveira, Gustavo Laine Araújo de-
dc.contributor.authorGomes, Ciro Martins-
dc.date.accessioned2023-10-25T14:29:31Z-
dc.date.available2023-10-25T14:29:31Z-
dc.date.issued2023-05-10-
dc.identifier.citationMONTEZUMA, Thais et al. Effectiveness and safety of multidrug therapy containing clofazimine for paucibacillary leprosy and clarithromycin for rifampicin-resistant leprosy: a systematic review and meta-analysis. Frontiers in Medicine, v. 10, 2023. DOI: https://doi.org/10.3389/fmed.2023.1139304. Disponível em: https://www.frontiersin.org/articles/10.3389/fmed.2023.1139304/full. Acesso em: 25 out. 2023.pt_BR
dc.identifier.urihttp://repositorio2.unb.br/jspui/handle/10482/46737-
dc.language.isoengpt_BR
dc.publisherFrontierspt_BR
dc.rightsAcesso Abertopt_BR
dc.titleEffectiveness and safety of multidrug therapy containing clofazimine for paucibacillary leprosy and clarithromycin for rifampicin-resistant leprosy: a systematic review and meta-analysispt_BR
dc.typeArtigopt_BR
dc.subject.keywordHanseníasept_BR
dc.subject.keywordMeta-análisept_BR
dc.subject.keywordResistência a medicamentospt_BR
dc.rights.licenseCOPYRIGHT © 2023 Montezuma, Vernal, Andrade, Brandão, de Oliveira and Gomes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these termpt_BR
dc.identifier.doihttps://doi.org/10.3389/fmed.2023.1139304pt_BR
dc.description.abstract1Introduction: The present study aimed to evaluate leprosy cure and relapse rates as primary outcomes related to two additional strategies for leprosy treatment: clofazimine for paucibacillary (PB) leprosy patients and clarithromycin for patients with rifampicin-resistant leprosy. Methods: We conducted two systematic reviews (protocols CRD42022308272 and CRD42022308260). We searched the PubMed, EMBASE, Web of Science, Scopus, LILACS, Virtual Health Library and Cochrane Library databases, registers of clinical trial databases and gray literature. We included clinical trials evaluating the addition of clofazimine to PB leprosy treatment and the use of clarithromycin for treating patients with rifampicin-resistant leprosy. Risk of bias (RoB) in randomized clinical trials was assessed by the RoB 2 tool and that in non-randomized clinical trials was assessed by the ROBINS-I tool; and the certainty of the evidence was assessed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. A meta-analysis of dichotomous outcomes was performed. Results: For clofazimine, four studies were included. Cure and relapse rates were not dierent with the addition of clofazimine to PB leprosy treatment and demonstrated very low certainty of evidence. For clarithromycin, six studies were included. Considerable heterogeneity resulted from the dierence between comparators, and studies showed no dierence in the assessed outcomes with the addition of clarithromycin to rifampicin-resistant leprosy treatment. Mild adverse events were reported for both drugs but did not significantly impact treatment. Discussion: The eectiveness of both drugs still needs to be determined. Adding clofazimine to PB leprosy treatment may reduce the repercussions of an incorrect operational classification with no apparent relevant side.pt_BR
dc.contributor.affiliationHealth Technology Assessment Unit, Hospital Alemão Oswaldo Cruzpt_BR
dc.contributor.affiliationInstituto de Medicina Tropical de São Paulo, Universidade de São Paulopt_BR
dc.contributor.affiliationMinistério da Saúde do Brasil, Coordenação-Geral de Vigilância das Doenças em Eliminaçãopt_BR
dc.contributor.affiliationMinistério da Saúde do Brasil, Coordenação-Geral de Vigilância das Doenças em Eliminaçãopt_BR
dc.contributor.affiliationUniversidade de Brasília, Programa de Pós-Graduação em Ciências Médicaspt_BR
dc.contributor.affiliationMinistério da Saúde do Brasil, Coordenação-Geral de Vigilância das Doenças em Eliminaçãopt_BR
dc.contributor.affiliationUniversidade de Brasília, Programa de Pós-Graduação em Ciências Médicaspt_BR
dc.contributor.affiliationUniversidade de Brasília, Programa de Pós-Graduação em Patologia Molecularpt_BR
dc.description.unidadeFaculdade de Medicina (FM)pt_BR
Aparece nas coleções:Artigos publicados em periódicos e afins

Mostrar registro simples do item Visualizar estatísticas



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.